Status:
COMPLETED
Immune Activation Markers in HIV-infected Patients Switching to Long Acting Dual Therapy
Lead Sponsor:
Centre Hospitalier de Cannes Simone Veil
Conditions:
HIV-1-infection
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of the study is to measure the impact on immune activation and inflammatory markers of switching from a triple combination antiretroviral therapy (cART) to a long acting dual therapy in HI...
Detailed Description
Patients meeting the inclusion criteria will be offered to participate to the study. In case of acceptance by given their writting consent, 6 ml of blood will be collected for measuring immune activa...
Eligibility Criteria
Inclusion
- Patients agreeing to participate to the study and to collect their data
- HIV-1 infected subjects
- Patients switching from a stable (at least 6 months) and successful triple cART to a long acting dual cART
- Patients older than 18 yrs and regularly followed in Cannes and Nice hospitals
- Patients with a healthcare card
Exclusion
- HIV-2 infected subjects
- Patients not being on successful and stable cART
- Patients having being treated during acute HIV-infection
- Patients modifying cART for virological failure
- Subjects modifying their treatment for another combination than from a triple cART to a dual cART
- Patients modifying cART during the 6 months of follow-up
- Patients refusing to participate to the study
- Patients included in an interventional study during the 6 months of follwo-up
- Patient under juridical procedure
Key Trial Info
Start Date :
July 28 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 17 2023
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05433987
Start Date
July 28 2022
End Date
November 17 2023
Last Update
August 28 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nathalie DOUX
Cannes, France, 06414